Hudson Bay Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,025,000
Closed -$2.83M 1242
2021
Q1
$2.83M Sell
1,025,000
-250,284
-20% -$755K 0.03% 460
2020
Q4
$3.1M Buy
1,275,284
+45,284
+4% +$109K 0.03% 303
2020
Q3
$2.58M Buy
1,230,000
+16,861
+1% +$56.8K 0.04% 324
2020
Q2
$4.58M Sell
1,213,139
-196,280
-14% -$588K 0.08% 210
2020
Q1
$2.66M Sell
1,409,419
-665,581
-32% -$1.73M 0.07% 228
2019
Q4
$4.34M Buy
2,075,000
+600,000
+41% +$1.15M 0.1% 191
2019
Q3
$3.52M Buy
1,475,000
+215,000
+17% +$577K 0.1% 195
2019
Q2
$3.94M Buy
1,260,000
+260,000
+26% +$955K 0.09% 206
2019
Q1
$4.98M Hold
1,000,000
0.06% 276
2018
Q4
$4.48M Buy
1,000,000
+324,900
+48% +$1.59M 0.06% 325
2018
Q3
$3.27M Buy
675,100
+400,100
+145% +$2.05M 0.04% 377
2018
Q2
$1.65M Buy
275,000
+30,000
+12% +$219K 0.02% 552
2018
Q1
$2.17M Sell
245,000
-5,000
-2% -$37.4K 0.05% 436
2017
Q4
$1.81M Buy
+250,000
New +$1.56M 0.04% 337

Other funds holding SBBP

Hudson Bay Capital Management's SBBP Position: Q2 2021 in Review

Hudson Bay Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2021, closing a stake of 1,025,000 shares — an estimated $2.83M sold.

Hudson Bay Capital Management first reported a position in SBBP in Q4 2017 and held it in 14 quarters. The position peaked at $4.98M in Q1 2019. 59 funds tracked by Wall St. Rank hold SBBP as of Q2 2021.

  • Hudson Bay Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q2 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,025,000 Strongbridge Biopharma plc. shares in Q2 2021, an estimated $2.83M.
  • Hudson Bay Capital Management first reported a position in Strongbridge Biopharma plc. in Q4 2017 and held it in 14 quarters.
  • Hudson Bay Capital Management's Strongbridge Biopharma plc. position peaked at $4.98M in Q1 2019.
  • 59 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2021.

Based on Hudson Bay Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.